Company profile · Sponsor
Mundipharma
Mundipharma GmbH
- Pipeline
- 2
- Drugs
- 0
- Patents
- 0
Quick answer
Mundipharma (E39A946) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (2)
Search pipeline →-
Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets
Mundipharma
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)
1 trial -
REZZAYO 200 mg powder for concentrate for solution for infusion
Mundipharma
Chronic pulmonary aspergillosis (CPA)
1 trial
Frequently asked questions
What is Mundipharma?
Mundipharma (E39A946) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Mundipharma sponsor?
We track 2 ClinicalTrials.gov-linked programs for Mundipharma, including Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets and 1 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Mundipharma company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.